Evidence status: CURRENT INITIAL-PRESCRIBING, PMP, RISK-ASSESSMENT, AND INFORMED-CONSENT FRAMEWORK. Nevada’s prescription medication agreement sits inside a broader statutory system that begins before the first covered controlled-substance prescription is issued.
PMP review
Before issuing an initial prescription for a Schedule II-IV controlled substance or a Schedule V opioid, the practitioner generally must obtain and review the patient’s utilization report from Nevada’s prescription-monitoring system. The report must be reviewed at least once every 90 days during the course of treatment, subject to statutory exceptions.
Initial evaluation
Before the first covered Schedule II-IV prescription for pain, the practitioner must establish a bona fide relationship, perform an evaluation and risk assessment, establish a preliminary diagnosis and individualized treatment plan, document why a controlled substance is being used instead of a non-controlled alternative, and obtain informed consent.
Risk assessment
The evaluation must include relevant medical history, a pain-focused physical examination, assessment of mental health and risk of abuse/dependency/addiction, and—when the intended prescription duration is at least 30 days—good-faith efforts to obtain and review relevant records from other providers.
Informed consent subjects
Informed consent must address, where applicable, risks and benefits, proper use, alternatives, key treatment-plan provisions, dependence/addiction/overdose risk, safe storage and disposal, refill practices, pregnancy-related risk, opioid-antagonist availability, and diversion risk involving minors.
Why these duties are separate from Contract for Care
PMP review, initial risk assessment, and informed consent are independent legal duties. A clinic agreement may repeat them, but their authority comes from Nevada statute, not merely from the contract language.
Primary sources
Reviewed: October 4, 2026.